Get started
Author

Eric Elenko

Observed names: E Elenko, E. Elenko, ERIC ELENKO
OpenAlex ID: A5030736446
Digital medicine's march on chronic disease
2016 · Joseph C Kvedar, Alexander L Fogel, et al. · Nature Biotechnology · 218
PDF
Defining digital medicine
2015 · Eric Elenko, Lindsay Underwood, et al. · Nature Biotechnology · 191
Increased expression of cytokine-induced neutrophil chemoattractant in septic rat liver
1996 · C. S. Deutschman, B. A. Haber, et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 40
Sepsis-induced depression of rat glucose-6-phosphatase gene expression and activity
1997 · Clifford S. Deutschman, Kenneth M. Andrejko, et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 30
A regulatory framework emerges for digital medicine
2015 · Eric Elenko, Austin Speier, et al. · Nature Biotechnology · 27
A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium‐Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases
2021 · Michael C. Chen, Christopher C. Korth, et al. · Clinical Pharmacology in Drug Development · 17
482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors
2021 · Aleksandra Filipovic, Zev Wainber, et al. · Regular and Young Investigator Award Abstracts · 11
PDF
Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial
2026 · Toby M Maher, Mark J Hamblin, et al. · American Journal of Respiratory and Critical Care Medicine · 3
Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial
2025 · T.M. Maher, M.A. Bergna, et al. · American Journal of Respiratory and Critical Care Medicine · 3
Phase 1 demonstrates LYT-100 (deupirfenidone) is dose-proportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect (FE)
2021 · Michael Chen, Christopher Korth, et al. · 2
US immigration order strikes against biotech
2017 · Jeremy M Levin, Steven H Holtzman, et al. · Nature Biotechnology · 2
Late Breaking Abstract - ELEVATE IPF phase 2b open-label extension demonstrates durable efficacy of deupirfenidone
2025 · ARGYRIS TZOUVELEKIS, Mark J. Hamblin, et al. · 1
A phase 2b randomized trial to evaluate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF)
2022 · P Ford, V Cottin, et al. · 12.01 - Idiopathic interstitial pneumonias · 1
Deupirfenidone (LYT-100) Reduces Incidence of Gastrointestinal (GI)-Related Adverse Events (AEs) Compared to Pirfenidone at Comparable Exposure Levels: A Phase 1, Double-Blind, Randomized Crossover Study in Older Healthy Subjects
2022 · M. Chen, E. Elenko, et al. · 1
Erratum: Defining digital medicine
2016 · Eric Elenko, Lindsay Underwood, et al. · Nature Biotechnology · 1
Elevate Ipf Phase 2b Results (deupirfenidone Vs. Placebo and Pirfenidone) in Patients Aged ≥75 Compared With <75 Years
2025 · TEJASWINI KULKARNI, MIGUEL A BERGNA, et al. · CHEST Journal
A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults
2025 · Toby M. Maher, Michael C. Chen, et al. · ERJ Open Research
51. A First-In-Human Phase I Study of LYT-300, a First-In-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone That is Absorbed via the Lymphatic System
2024 · James Shipley, Varun Garg, et al. · Biological Psychiatry
52. LYT-300, an Oral Prodrug of Allopregnanolone, Potently Reduces Salivary Cortisol Response to the Trier Social Stress Test in a Randomized, Placebo-Controlled Trial in Healthy Participants
2024 · Michael Chen, Mark Harnett, et al. · Biological Psychiatry
Deupirfenidone (lyt-100) Dose-selection Rationale for a Phase 2b Idiopathic Pulmonary Fibrosis (ipf) Study-elevate
2023 · TOBY M MAHER, MICHAEL C CHEN, et al. · CHEST Journal
PDF
Digital medicine's march on chronic
2016 · Alexander L. Fogel, Eric Elenko, et al.
Sepsis Induces the Expression of the Chemokine, Cinc, in Rat Hepatocytes
1995 · Clifford S. Deutschman, BA Haber, et al. · Critical Care Medicine
Works count: 22
Citation count: 548
H-index: 7
I10-index: 7
Year
Topic
Type